31 withdrawn. 31 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Withdrawn 31 |
| Phase 1 | 7 | Withdrawn 7 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Mouth Diseases: new trials by email Literature Review of Mouth Diseases trials Research Report on Mouth Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy Copaíba mouthwash, Placebo mouthwash - Oral Mucositis, Oral Mucositis (Ulcerative) Due to Radiation | Phase 2 | Withdrawn | Instituto Nacional de Cancer, Brazil | 2025-01-17 | 2026-10-09 | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial Ketamine Topical - Cancer of Head and Neck, Mucositis Oral | Phase 2 | Withdrawn | Northwell Health | 2022-09-19 | 2024-01-24 | |
| Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer Basic Oral Care + active LLLT, Basic oral Care + inactive LLLT, Basic Oral Care - Upper Aerodigestive Tract Neoplasms | Phase 2 | Withdrawn | Institut Claudius Regaud | 2021-03-01 | 2021-04-08 | |
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General Kovanaze Nasal Spray, Articaine Injection - Caries,Dental, Apical Periodontitis | Phase 2 | Withdrawn | Virginia Commonwealth University | 2020-09-01 | 2024-10-15 | |
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics Kovanaze Nasal Spray, Articaine Injection - Caries,Dental, Apical Periodontitis | Phase 2 | Withdrawn | Virginia Commonwealth University | 2020-08-01 | 2020-06-25 | |
| An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS) Ravaglimab, Ravagalimab, Placebo - Sjogren's Syndrome (SS) | Phase 2 | Withdrawn | AbbVie | 2020-03-06 | 2022-02-01 | |
| Apremilast - Oral Lichen Planus Trial Apremilast, Placebo - Oral Lichen Planus | Phase 2 | Withdrawn | Sunnybrook Health Sciences Centre | 2019-11-21 | 2020-06-25 | |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas FE 203799 - Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1 / Phase 2 | Withdrawn | GlyPharma Therapeutics | 2018-09-01 | 2024-10-24 | |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Lactobacillus acidophilus and Bifidobacterium lactis, Placebo - Periodic Fever, Aphthous Stomatitis | Phase 2 | Withdrawn | Connecticut Children's Medical Center | 2016-10-01 | 2018-01-24 | |
| Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome VAY736 lower dose, VAY736 higher dose - Primary Sjögren's Syndrome | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2015-12-01 | 2017-04-20 | |
| IV Acetaminophen in Children Undergoing Palatoplasty IV acetaminophen, Placebo - Cleft Palate | Phase 2 | Withdrawn | Nationwide Children's Hospital | 2015-12-01 | 2016-03-08 | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1 / Phase 2 | Withdrawn | James Chodosh, MD, MPH | 2014-11-01 | 2017-04-07 | |
| Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain ATNC05, Placebo - Atypical Facial Pain, Persistent Idiopathic Facial Pain | Phase 2 / Phase 3 | Withdrawn | Allodynic Therapeutics, Inc | 2014-03-01 | 2014-03-13 | |
| Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer therapeutic conventional surgery, intensity-modulated radiation therapy, cisplatin - Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx | Phase 2 | Withdrawn | Radiation Therapy Oncology Group | 2013-12-01 | 2015-03-20 | |
| Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TXA127 - Hematologic Malignancies | Phase 2 | Withdrawn | Tarix Pharmaceuticals | 2013-12-01 | 2016-08-31 | |
| Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation TXA127 - Hematologic Malignancies | Phase 2 | Withdrawn | Tarix Pharmaceuticals | 2013-12-01 | 2016-08-31 |
Showing 20 of 31. Sign in to see all of them.
Mucositis (7) · Head and Neck Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Stevens-Johnson Syndrome (4) · Stomatitis (4) · Hematologic Neoplasms (3) · Sjogren's Syndrome (3) · Behcet Syndrome (2) · Dental Caries (2) · Neoplasms (2) · Periapical Periodontitis (2) · Salivary Gland Neoplasms (2) · Tongue Neoplasms (2) · Trigeminal Neuralgia (2) · Arthritis (1)
Stomatognathic Diseases (31) · Neoplasms (11) · Neoplasms by Site (11) · Skin and Connective Tissue Diseases (11) · Immune System Diseases (10) · Skin Diseases (8) · Digestive System Diseases (7) · Gastroenteritis (7) · Gastrointestinal Diseases (7) · Eye Diseases (6) · Neoplasms by Histologic Type (6) · Pathological Conditions, Signs and Symptoms (6) · Hypersensitivity (5) · Neoplasms, Glandular and Epithelial (5)
Cisplatin (3) · Infliximab (3) · angiotensin I (1-7) (3) · Carboplatin (2) · Carticaine (2) · Fibroblast Growth Factor 7 (2) · Oxymetazoline (2) · Radiotherapy, Intensity-Modulated (2) · Tetracaine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Abatacept (1) · Acetaminophen (1) · Clobetasol (1) · Docetaxel (1)
Tarix Pharmaceuticals (3) · Virginia Commonwealth University (2) · AbbVie (1) · Actuate Therapeutics Inc. (1) · Allodynic Therapeutics, Inc (1) · Children's Oncology Group (1) · Connecticut Children's Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · GlyPharma Therapeutics (1) · Hadassah Medical Organization (1) · Institut Claudius Regaud (1) · Instituto Nacional de Cancer, Brazil (1) · James Chodosh, MD, MPH (1) · Liu Tian (1) · Loyola University (1)
United States (15) · Canada (2) · Brazil (1) · China (1) · France (1) · Israel (1) · Netherlands (1)
James Chodosh, MD, MPH (2) · Parthasarathy Madurantakam, DDS, PhD (2) · Anurag Singh (1) · Bhupesh Parashar, MD, DrPH (1) · Claes H Dohlman, MD, PhD (1) · Edmund K Waller, MD,PhD,FACP (1) · Emanual Maverakis, MD (1) · Floyd C. Holsinger (1) · George H. Yoo, MD (1) · Glenn J Hanna, MD (1) · Hagen Klieb, HBSc, MSc, DMD, FRCD(C) (1) · Harold E. Kim, MD (1) · Heath D Skinner (1) · Jeffrey J. Borckardt, Ph.D. (1)
2019 (1), K23NS050485 (1), U10CA021661 (1), U10CA032102 (1), U10CA095861 (1), U10CA180820 (1)